USANA Health Sciences Inc. (USNA) Major Shareholder Sells $1,463,500.00 in Stock
USANA Health Sciences Inc. (NYSE:USNA) major shareholder Global Ltd Gull sold 10,000 shares of the business’s stock in a transaction dated Wednesday, October 12th. The shares were sold at an average price of $146.35, for a total transaction of $1,463,500.00. Following the completion of the sale, the insider now directly owns 6,319,110 shares of the company’s stock, valued at approximately $924,801,748.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
Global Ltd Gull also recently made the following trade(s):
- On Wednesday, September 14th, Global Ltd Gull sold 10,000 shares of USANA Health Sciences stock. The shares were sold at an average price of $134.67, for a total transaction of $1,346,700.00.
- On Wednesday, August 10th, Global Ltd Gull sold 10,000 shares of USANA Health Sciences stock. The shares were sold at an average price of $135.08, for a total transaction of $1,350,800.00.
USANA Health Sciences Inc. (NYSE:USNA) opened at 144.70 on Friday. USANA Health Sciences Inc. has a 12 month low of $92.00 and a 12 month high of $150.00. The firm has a 50-day moving average of $138.91 and a 200 day moving average of $127.25. The firm has a market capitalization of $1.74 billion, a PE ratio of 19.07 and a beta of 1.34.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/14/usana-health-sciences-inc-usna-major-shareholder-sells-1463500-00-in-stock.html
USANA Health Sciences (NYSE:USNA) last issued its earnings results on Tuesday, July 26th. The company reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $2.05 by $0.02. The firm earned $258.50 million during the quarter, compared to analyst estimates of $256.66 million. USANA Health Sciences had a net margin of 10.07% and a return on equity of 34.15%. The company’s quarterly revenue was up 10.8% on a year-over-year basis. During the same quarter last year, the business earned $1.92 earnings per share. Equities research analysts forecast that USANA Health Sciences Inc. will post $8.10 earnings per share for the current year.
Institutional investors have recently modified their holdings of the company. Emerald Acquisition Ltd. acquired a new position in shares of USANA Health Sciences during the second quarter worth $4,619,000. Old Mutual Global Investors UK Ltd. raised its position in USANA Health Sciences by 174.8% in the second quarter. Old Mutual Global Investors UK Ltd. now owns 59,105 shares of the company’s stock worth $6,586,000 after buying an additional 37,595 shares during the period. BlackRock Institutional Trust Company N.A. raised its position in USANA Health Sciences by 15.8% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 163,822 shares of the company’s stock worth $18,255,000 after buying an additional 22,326 shares during the period. Teachers Advisors Inc. raised its position in USANA Health Sciences by 30.6% in the first quarter. Teachers Advisors Inc. now owns 87,383 shares of the company’s stock worth $10,610,000 after buying an additional 20,496 shares during the period. Finally, Barclays PLC raised its position in USANA Health Sciences by 1,181.8% in the first quarter. Barclays PLC now owns 17,432 shares of the company’s stock worth $2,109,000 after buying an additional 16,072 shares during the period. Hedge funds and other institutional investors own 41.86% of the company’s stock.
A number of equities analysts recently issued reports on USNA shares. Zacks Investment Research cut shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 28th. DA Davidson upped their price objective on shares of USANA Health Sciences from $135.00 to $150.00 and gave the stock a “neutral” rating in a research report on Thursday, July 28th. Three investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $149.11.
USANA Health Sciences Company Profile
USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. It operates as a direct selling company in approximately two geographic regions: Americas and Europe, and Asia Pacific, which includes approximately three sub-regions: Southeast Asia Pacific, Greater China and North Asia.
Receive News & Ratings for USANA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.